Oncolytics Biotech Inc. Files April 2024 6-K Report

Ticker: ONCY · Form: 6-K · Filed: Apr 2, 2024 · CIK: 1129928

Oncolytics Biotech INC 6-K Filing Summary
FieldDetail
CompanyOncolytics Biotech INC (ONCY)
Form Type6-K
Filed DateApr 2, 2024
Risk Levellow
Pages1
Reading Time1 min
Sentimentneutral

Sentiment: neutral

Topics: reporting, foreign-private-issuer, administrative

Related Tickers: ONCY

TL;DR

ONCOLYTICS BIOTECH INC (ONCY) filed its monthly 6-K, confirming foreign private issuer status and 20-F filing.

AI Summary

Oncolytics Biotech Inc. filed a Form 6-K on April 2, 2024, reporting as a foreign private issuer. The company is based in Calgary, Alberta, Canada, and operates in the Pharmaceutical Preparations industry. This filing is for the month of April 2024 and indicates they file annual reports under Form 20-F.

Why It Matters

This filing provides routine updates for foreign private issuers, informing investors about the company's ongoing reporting status and administrative details.

Risk Assessment

Risk Level: low — This is a routine administrative filing for a foreign private issuer and does not contain significant new financial or operational information.

Key Players & Entities

FAQ

What is the primary purpose of this Form 6-K filing?

This Form 6-K is a Report of Foreign Private Issuer filed pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934, for the month of April 2024.

What is the company's legal and administrative status as indicated in the filing?

The filing indicates that Oncolytics Biotech Inc. is a foreign private issuer and files its annual reports under Form 20-F.

Where is Oncolytics Biotech Inc. headquartered?

Oncolytics Biotech Inc. is headquartered in Calgary, Alberta, Canada, with its principal executive offices located at Suite 804, 322 11th Avenue SW, Calgary, Alberta, T2R 0C5.

What is the SIC code for Oncolytics Biotech Inc.?

The Standard Industrial Classification (SIC) code for Oncolytics Biotech Inc. is 2834, which corresponds to Pharmaceutical Preparations.

Does this filing indicate submission in paper format?

The filing includes checkboxes for submitting Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1), but the specific status for this filing is not explicitly checked or detailed in the provided text.

Filing Stats: 334 words · 1 min read · ~1 pages · Grade level 17.1 · Accepted 2024-04-02 08:02:42

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Oncolytics Biotech Inc. (Registrant) By s Kirk Look Date April 2, 2024 Kirk Look Chief Financial Officer

View Full Filing

View this 6-K filing on SEC EDGAR

View on Read The Filing